Identification of critical genes which play pivotal roles in controlling tumor growth and survival will establish the basis for developing therapeutic targets. With the aim of establishing personalized medicine for treatment of solid tumors, we focused on MET amplification in gastric cancer patients, given the extreme sensitivity to c-Met inhibitor in MET amplified gastric cancer cell lines. We tested MET amplification and activation of c-Met in various gastric cancer cell lines and tissue samples from 482 gastric cancer patients who underwent curative surgery. Gastric cancer cell lines with MET amplification by quantitative real-time PCR (qPCR) and FISH predicted sensitivity to PHA-665,752, a selective c-Met kinase inhibitor. Of the 472 patients who had DNA sample available for qPCR analysis, 100 patients (21.2%) had a MET copy number greater than 4.0 copies and demonstrated poorer survival following curative surgery with statistical significance (5-year OS; 50.0 vs. 59.1%; MET amplification (+) vs. MET amplification (-); P=0.0134). These results suggest that the increased MET copy number measured by qPCR plays an important role in determining prognosis in gastric cancer patients. However, the predictive role of MET amplification for treatment response should be further explored in upcoming clinical trials.
Introduction
Gastric cancer is the leading cause of cancer death worldwide with the incidence of 18.9/100,000 per year (1) . The incidence of gastric cancer was estimated to be 934,000 cases, with 56% of the new cases occurring in East Asia (2) . Gastric cancer accounts for 20.8% of all cancers in Korea according to the Central Tumor Registry data for 2002 (3) . Although overall survival of gastric cancer has been enhanced owing to the application of national fiberoptic esophagogastroduodenoscopy (EGD) screening program in adults aged over 40 years in Korea, a large proportion of patients are still diagnosed at metastatic stage. The median survival time following cytotoxic chemotherapy is still less than 1 year and thus, metastatic gastric cancer remains a therapeutic challenge for medical oncologists. The role of molecularly targeted therapy has not been adequately explored in gastric cancer when compared to other common solid tumors such as non-small cell lung cancer, breast or colorectal cancer.
The MET oncogene encodes the receptor tyrosine kinase (RTK) for hepatocyte growth factor (HGF) and controls genetic programs leading to cell growth, invasion and protection from apoptosis (4) . Although the definitive role of MET oncogene is yet to be determined in carcinogenesis of gastric cancer, overexpression and amplification of c-Met has been demonstrated in gastric cancer cell lines (5) (6) (7) (8) (9) . In addition, approximately 10-20% of gastric cancer tissues and up to 40% of the scirrhous histological subtype were shown to harbor increased MET gene copy numbers (6, 10, 11) . Importantly, PHA-665,752, a selective c-Met kinase inhibitor showed significant reduction of established tumor mass in mouse xenografts with GTL16, a gastric cancer cell line with >10-fold MET amplification (5, 12) . Another pivotal study showed that gastric cancer cells with MET amplification were extremely sensitive to PHA-665,752 and implicated a potential role of c-Met protein in developing theranostics in gastric cancer (13) . Due to limited number of patients in previous studies,
Impact of MET amplification on gastric cancer:
Possible roles as a novel prognostic marker and a potential therapeutic target We undertook this study to assess the impact of c-Met overexpression, c-Met activation, and MET amplification on survival of gastric cancer patients.
Materials and methods

Patients and tissues.
We have previously reported the outcome of 544 stage II-IV (M0) gastric cancer patients, who received adjuvant chemoradiation therapy after curative surgery (14) . Of these patients and additional 23 stage IB patients who were included in our previous study, formalin-fixed paraffin-embedded primary tumor tissues were available from 482 patients. The postoperative adjuvant treatment adopted was the same as that used for the INT-0116 (SWOG-9008) trial and the results were previously reported (15) . All patients provided written informed consent according to the institutional guideline and the study was approved by the Institutional Review Board. The clinical and pathological features of the patients are shown in Table I . The median age was 54 (range 23-70) years. By Lauren classification, 29.9% of patients had intestinal type. All patients received D2 or greater lymph node dissection and 34.3% of patients had stage IB or II. After a median follow-up duration of 110.7 months (84.9-155.4 months), a 5-year overall survival (OS) rate was 57.7% and a 5-year disease-free survival (DFS) rate was 56.4%.
Cell culture and cell growth assay. Human gastric carcinoma cells, MKN-1, MKN-45, MKN-74, N87 SNu-1, SNu-5, SNu-484, SNu-638 and SNu-668 cells were purchased from the Korean Cell Line Bank (Seoul, Korea). YCC-2, YCC-3 and YCC-7 were kindly provided by Dr Hyun Cheol Chung (Yonsei Cancer Center, Seoul, Korea). YCC-2, YCC-3 and YCC-7 were maintained in DMEM (Gibco-BRL, Carlsbad, CA) supplemented with 10% heat-inactivated FBS, 100 units/ml penicillin, 100 units/ml streptomycin, and 2 mM glutamine; the others were cultured in RPMI-1640 medium (Gibco-BRL) supplemented with 10% heat-inactivated FBS, 100 units/ml penicillin, 100 units/ml streptomycin, and 2 mM glutamine. All cells were incubated in a humidified atmosphere contained 5% CO 2 at 37˚C.
Growth and inhibition of growth were assessed by the 5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay according to previously established methods (16) . PHA-665,752 was purchased from Tocris Bioscience (Ellisville, MO). Stock solution of 10 mM was prepared in DMSO and stored at -20˚C.
Antibodies and Western blotting. Cells grown under the previously specified conditions were lysed in the following lysis buffer composition: 20 mM/l Tris (pH 7.4), 150 mM/l NaCl, 1% NP40, 10% glycerol, 1 mM/l EDTA, 1 mM/l EGTA, 5 mM/l sodium pyrophosphate, 50 mM/l NaF, 10 nM/l β-glycerophosphate, 1 mM/l sodium vanadate, 0.5 mM/l DTT, 4 µg/ml leupeptin, 4 µg/ml pepstatin, 4 µg/ml apoprotein, and 1 mM/l phenylmethylsulfonyl fluoride. Lysates were centrifuged at 16,000 × g for 5 min at 4˚C. The supernatant was used for subsequent procedures. Western blot analyses were performed according to the antibody manufacturer's recommendations. Antibody binding was detected using an enhanced chemiluminescence system (Perkin-Elmer, Waltham, MA). Anti-Met and anti-phospho-Met antibodies were from Cell Signaling Technology (Beverly, MA). Anti-phosphotyrosine (4G10) antibody was from upstate Biotechnology (Lake Placid, NY).
Quantitative real-time PCR (qPCR).
The MET and MTHFR (endogenous control) levels were evaluated using the following primers and methods previously published (17) . . MET amounts were interpolated from the standard curves and normalized to MTHFR amounts. Normal DNAs from non-malignant gastric tissues and normal blood lymphocytes of healthy volunteers were used as reference DNAs for each PCR reaction. We also performed qPCR analysis using TaqMan primers which are directed at exon 2 of MET and have been previously described (13, 16) . The results of the relative copy number for MET by two different methods were not different in the gastric cancer cell line and gastric cancer tissues (data not shown). We also carried out corresponding fluorescent in situ hybridization (FISH) on these specimens.
Immunohistochemistry. Tissue microarray (TMA) blocks were sectioned with 4 µm thickness. Immunohistochemical study was performed using the streptavidin-biotin complex method and TechMate™ 1000 automated staining system (DakoChemmate, Glostrup, Denmark). Primary antibodies used and working dilutions employed were as follows; c-Met (24H2, Cell Signaling Technology; 1:100) phospho-Met (pY1349, Cell Signaling Technology; 1:100). Deparaffinized sections were treated with 3% hydrogen peroxide in methanol for 10 min to inhibit endogenous peroxidase. Sections were immersed in 0.01 M citrate buffer (pH 6.0) and heated in a pressure cooker for 30 min. Sections were then incubated with primary antibody for 50 min at room temperature. Each section was treated sequentially with biotinylated secondary antibody (anti-mouse immunoglobulin) and streptavidinperoxidase complex (DakoChemmate). 3,3'-diaminobenzidine tetrahydrochloride was used as a chromogen, and then Mayer's hematoxylin counterstain was applied. Negative controls (isotype-matched irrelevant antibody) were run simultaneously. The results of staining were evaluated by two independent pathologists (S.J.W. and K.M.K.), who were blinded to the clinical data and the difference in interpretation was resolved by consensual agreement. Total Met-staining cells exhibited a combined membranous and cytoplasmic pattern, whereas phosphorylated Met-staining cells showed nuclear staining in addition to the combined membranous and cytoplasmic pattern. For assessment of the positivity of immunostaining for each section, the staining intensity was graded on the following scale: 0, no staining; 1, weak staining; 2, moderate staining; and 3, intense staining, and nuclear staining of phospho-Met in >5% of tumor cells was regarded as positive. Positive cells were counted by monitoring at least 1,000 cancer cells from more than five high power fields where positive cells were present at a relatively uniform density.
FISH. FISH was performed according to the established protocol using a D7S522 probe and chromosome 7 centromere probe (CEP7) purchased from Vysis (Des Plaines, IL) (16) . Four micron (4 µm) tumor sections generated from TMA blocks were pretreated by deparaffinizing in xylene and dehydrating in ethanol. The sections were immersed in Tris-base and EDTA (TE), washed in phosphate-buffered saline (PBS), and then treated with Digest-All (Zymed, San Francisco, CA). Sections were then fixed with formalin and dehydrated in ethanol. After co-denaturation of the tissue and the probe mixture (D7S522 and CEP7) at 70˚C for 3 min, the sections were hybridized at 37˚C for 48-72 h, washed with sodium citrate and Tween-20 containing buffers and counterstained with DAPI. One hundred cells from each TMA core were analyzed and the number of D7S522 and CEP7 signals determined.
Statistical analyses. Disease-free survival (DFS) was defined as the time from surgery to the first relapse of cancer, or death of any cause. Overall survival (OS) was calculated from the date of surgery to the date of death. OS and DFS were calculated using the Kaplan-Meier method. Correlation analyses were performed using the two sided χ 2 test or Fisher's exact test. Differences in disease-free and overall survival were compared using log-rank tests and Cox proportional hazard analysis. P-value <0.05 was considered statistically significant.
Results
MET amplification and constitutive activation in human gastric cancer cells.
Immunoblotting analysis showed heterogeneous phosphotyrosine and various levels of c-Met expression in a panel of gastric cancer cell lines. Immunoblotting using phospho-Met antibodies against Y1349 showed constitutive phosphorylation of the receptor in cells with MET amplification, whereas cells without amplification had low levels of c-Met phosphorylation (Fig. 1A) . Analysis of the gastric cancer cell lines using qPCR identified the increased MET gene copy number which predicted sensitivity to PHA-665,752 (Fig. 1B) . We also confirmed MET amplification in SNu-5, SNu-638 and MKN-45 by FISH.
Correlation between MET amplification and clinical variables.
Of the 472 patients who had DNA sample available for qPCR analysis, 100 (21.2%) of the patients had MET copy number >4.0. Of the 100 patients who had amplified MET gene, 84 patients had 4.0-6.0 copies, 10 patients 6.0-8.0 copies, and 6 patients had 8.0-16 copies. The clinical features between the patients with MET amplification and those without amplification were not significantly different (Table II) . There was a trend toward more advanced N stage in patients with MET amplification, but there was no statistical significance (P=0.060).
Correlation between MET amplification, c-Met protein expression and c-Met activation.
In order to determine the most influential and important factors reflective of c-Met status, we tested MET amplification along with c-Met protein expression and c-Met activation which were evaluated by immunohistochemical staining against c-Met protein and phospho-Met (pY1349), respectively. In total, 452 specimens were interpretable for c-Met protein expression and activated phosphorylated Met expression. The representative immunohistochemical staining for activated c-Met is shown in Fig. 2A-F . Of the 103 tumor samples with c-Met activation identified by staining against phospho-Met (pY1349), 30 (29.1%) had MET amplification (≥4 copies) (P=0.026, Table III ). In contrast, a concordance rate between c-Met protein expression and MET amplification was only 17.9% (32 of 179 samples) (Table III) . Of the 472 samples evaluated, FISH analysis was successfully performed in 309 tissue samples (Fig. 2G) . Thirty-one patients (10.0%) exhibited FISH positivity for MET gene and the concordance rate between MET amplification assessed by qPCR and FISH was only 58.1%; 18 of 31 FISH(+) patients had MET amplification (data not shown).
Impact of MET amplification on recurrence and survival.
We performed survival analyses according to the c-Met status (Fig. 3) . Gastric cancer patients with MET amplification had a significantly shorter disease-free survival following curative surgery In subgroup analyses, there was a trend toward poorer prognosis in the subset of patients with MET amplification and c-Met protein activation (n=30) when compared with those without MET amplification or c-Met protein activation (n=283) (5-year OS; 50.0 vs. 57.9%, respectively; P=0.1317).
MET amplification -------------------------------------------------------------------------------------------------------------------
In localized disease (stage I/II), however, concurrent detection MET amplification with c-Met protein activation significantly predicted worse survival when compared with those without the two variables with statistical significance (5-year OS; 53.8 vs. 75.9%, respectively; P=0.0409, Fig. 3B ).
Discussion
Recently, gastric cancer cells with high-level stable chromosomal amplification of the growth factor receptor MET were shown to be extraordinarily susceptible to the c-Met selective inhibitor PHA-665752 (13). Identification of critical genes which play pivotal role in controlling tumor growth and survival will establish the basis for developing therapeutic targets. The most successful example of such identification of critical genes leading to overall improvement in treatment outcome is amplification of a locus on chromosome 17q which targets the HER2 growth factor receptor and the use of trastuzumab in HER2 amplified breast cancer. To establish personalized medicine for the treatment of solid tumors, we focused on MET amplification in gastric cancer patients given the extreme sensitivity to c-Met inhibitor in MET amplified gastric cancer cell lines (13) . We performed qPCR to determine the status of MET amplification in DNA samples from curatively resected gastric cancer tissues. Of the 472 patients who had DNA sample available for qPCR analysis, 100 (21.2%) of the patients had MET amplification. Of note, gastric cancer patients with MET amplification had a significantly shorter disease-free survival 
Negative ( (20) . In addition, an interim analysis of phase II study on 18 evaluable gastric cancer patients demonstrated that c-Met inhibitor (GSK089) was feasible with manageable toxicities and 8% MET amplification rate (21) . We plan to investigate whether treatment with c-Met inhibitor will actually confer survival benefit in this particular subset of patients.
Because a large-scaled analysis on c-Met status has not been performed in gastric cancer tissues or DNA samples, the cut-off value for MET amplification or c-Met protein expression and/or activation has not been standardized yet. Based on our experience, the FISH analysis was less feasible when compared with qPCR in assessing the MET amplification status. Of the 472 samples, only 309 samples yielded adequate FISH results for interpretation and of those, only 31 patients (10%) demonstrated MET amplification by FISH. The relatively low levels of concordance between MET amplification by qPCR and the FISH results might be due to tumor heterogeneity. TMA blocks were made by taking 2-mm sized core biopsies from individual formalin fixed paraffinembedded (FFPE) gastric cancer tissues whereas genomic DNA for qPCR was prepared from FFPE sections following dissection of tumor to obtain sufficient tumor cell content. To test the tumor heterogeneity, therefore we repeated FISH analysis in selected cases with available tissue specimens.
Considerable attention has been focused on the role of MET amplification in tumorigenesis and in resistance mechanism to tyrosine kinase inhibitor since Engelman et al reported that MET amplification induced resistance to gefitinib in a gefitinib-sensitive lung cancer cell line and a c-Met tyrosine kinase inhibitor (PHA-665,752) restored gefitinib sensitivity (16) . Since the molecular targeted therapy has been less extensively studied in gastric cancer as compared to non-small cell lung cancer, the role of MET amplification in such context needs to be defined in gastric cancer as well.
Taken together, we showed for the first time that MET is amplified in both cell lines and tumor tissues from gastric cancer patients. Importantly, MET amplification measured by qPCR was associated with shorter DFS and poorer OS but not c-Met protein overexpression or c-Met protein activation. Thus, MET amplification should be performed in addition to immunohistochemical studies for c-Met overexpression and c-Met activation (phosphorylated c-Met protein) as correlative analyses in clinical trials incorporating c-Met inhibitors. These studies may uncover a predictive role of MET amplification for treatment response, which should be also explored further as a novel therapeutic target in clinical trials.
